Who Buys Gatifloxacin from India — 93 Importers Behind a $802.0K Market

The importation of Gatifloxacin from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like SWASTIK PHARMACEUTICALS LTD in Uganda and HAWKARY PHARMACEUTICAL CO. in Iraq function as intermediaries, procuring Gatifloxacin in bulk for distribution to pharmacies, hospitals, and clinics. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.

• Hospital Groups: Organizations such as THE LUKE COMMISSION in Eswatini and GLADPHARM LTD. in Ukraine represent hospital networks that import Gatifloxacin directly for in-house use. Their procurement is typically based on patient demand and treatment protocols, leading to periodic, sizable orders aligned with their clinical needs.

• Government Procurement Agencies: Entities like the DIRECTORATE OF PROCUREMENT in Myanmar are responsible for national healthcare procurement. They often engage in tender-based purchasing, acquiring large quantities of Gatifloxacin to supply public health facilities. Their buying behavior is influenced by government budgets, public health policies, and disease prevalence, resulting in substantial, scheduled orders.

• Retail Chains: Companies such as JAZEERA & GULF CO in Yemen and IC PHARMA LAO CO., LTD in Laos operate pharmacy chains that import Gatifloxacin to stock their outlets. Their procurement is driven by consumer demand, leading to frequent, moderate-sized orders to ensure product availability across their retail locations.

• Re-exporters: Some buyers may act as re-exporters, purchasing Gatifloxacin for redistribution to neighboring countries or regions. This segment's purchasing behavior is opportunistic, capitalizing on market demands and trade agreements, resulting in variable order sizes and frequencies.

• Contract Manufacturers: Entities like M/S. ENSIGHT PHARMACEUTICALS INC in the Philippines may import Gatifloxacin as an active pharmaceutical ingredient (API) for local formulation and packaging. Their procurement is typically in bulk quantities, aligned with production schedules and market demand forecasts.

Understanding these segments is crucial for tailoring marketing strategies, forecasting demand, and ensuring efficient supply chain management.

The importation of Gatifloxacin into the top five importing countries involves specific regulatory processes:

• Iraq:
• Regulatory Authority: Iraqi Ministry of Health.
• Import Registration Process: Importers must obtain approval from the Iraqi Ministry of Health, which includes submitting product dossiers, certificates of analysis, and compliance with local pharmaceutical standards.
• Estimated Timeline for Registration: Approximately 6-12 months, depending on the completeness of documentation and regulatory reviews.
• Import Tariff/Duty for HS 30049099: Typically ranges from 5% to 10%, subject to changes based on government policies.

• Uganda:
• Regulatory Authority: National Drug Authority (NDA).
• Import Registration Process: Requires submission of a product dossier, including manufacturing licenses, GMP certificates, and product samples.
• Estimated Timeline for Registration: Approximately 6-9 months.
• Import Tariff/Duty for HS 30049099: Generally around 0% to 5%, with potential exemptions for essential medicines.

• Ukraine:
• Regulatory Authority: State Service of Ukraine on Medicines and Drugs Control.
• Import Registration Process: Involves submission of a comprehensive dossier, including clinical trial data, GMP compliance, and product labeling in Ukrainian.
• Estimated Timeline for Registration: Approximately 12-18 months.
• Import Tariff/Duty for HS 30049099: Typically around 5%, with possible reductions for essential medicines.

• Saudi Arabia:
• Regulatory Authority: Saudi Food and Drug Authority (SFDA).
• Import Registration Process: Requires submission of product dossiers, GMP certificates, and compliance with SFDA guidelines.
• Estimated Timeline for Registration: Approximately 6-12 months.
• Import Tariff/Duty for HS 30049099: Generally 5%, with potential exemptions for certain pharmaceuticals.

• Eswatini:
• Regulatory Authority: Eswatini Medicines Regulatory Authority (EMRA).
• Import Registration Process: Involves submission of product information, GMP certificates, and adherence to EMRA guidelines.
• Estimated Timeline for Registration: Approximately 6-9 months.
• Import Tariff/Duty for HS 30049099: Typically around 0% to 5%, with possible exemptions for essential medicines.

Importers should consult the respective regulatory authorities for the most current information, as regulations and tariffs are subject to change.

The demand for Gatifloxacin in importing countries is influenced by several factors:

• Disease Prevalence: Gatifloxacin is used to treat various bacterial infections, including respiratory tract infections and certain types of tuberculosis. High prevalence rates of these conditions in countries like Iraq and Uganda drive the need for effective antibiotics.

• Government Healthcare Programs: National health initiatives aimed at combating infectious diseases often include antibiotics like Gatifloxacin in their treatment protocols. For instance, Uganda's Ministry of Health has programs targeting respiratory infections, necessitating a steady supply of appropriate medications.

• Universal Health Coverage Expansion: Efforts to expand healthcare access, particularly in developing nations, increase the demand for essential medicines. As more individuals gain access to healthcare services, the need for antibiotics like Gatifloxacin rises correspondingly.

• WHO Essential Medicines List Procurement: While Gatifloxacin is not currently listed on the WHO Model List of Essential Medicines, its inclusion in national essential medicines lists can influence procurement decisions. Countries often align their procurement with WHO recommendations to ensure the availability of critical medications.

• Tender-Based Purchasing: Many governments and large healthcare organizations procure medicines through tender systems, which can lead to bulk purchasing of antibiotics like Gatifloxacin. This approach ensures cost-effectiveness and consistent supply for public health facilities.

With 93 buyers across 46 countries, the market for Gatifloxacin demonstrates a broad and diverse demand base, presenting opportunities for suppliers to cater to varying healthcare needs globally.

The importation of Gatifloxacin from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like SWASTIK PHARMACEUTICALS LTD in Uganda and HAWKARY PHARMACEUTICAL CO. in Iraq function as intermediaries, procuring Gatifloxacin in bulk for distribution to pharmacies, hospitals, and clinics. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.

• Hospital Groups: Organizations such as THE LUKE COMMISSION in Eswatini and GLADPHARM LTD. in Ukraine represent hospital networks that import Gatifloxacin directly for in-house use. Their procurement is typically based on patient demand and treatment protocols, leading to periodic, sizable orders aligned with their clinical needs.

• Government Procurement Agencies: Entities like the DIRECTORATE OF PROCUREMENT in Myanmar are responsible for national healthcare procurement. They often engage in tender-based purchasing, acquiring large quantities of Gatifloxacin to supply public health facilities. Their buying behavior is influenced by government budgets, public health policies, and disease prevalence, resulting in substantial, scheduled orders.

• Retail Chains: Companies such as JAZEERA & GULF CO in Yemen and IC PHARMA LAO CO., LTD in Laos operate pharmacy chains that import Gatifloxacin to stock their outlets. Their procurement is driven by consumer demand, leading to frequent, moderate-sized orders to ensure product availability across their retail locations.

• Re-exporters: Some buyers may act as re-exporters, purchasing Gatifloxacin for redistribution to neighboring countries or regions. This segment's purchasing behavior is opportunistic, capitalizing on market demands and trade agreements, resulting in variable order sizes and frequencies.

• Contract Manufacturers: Entities like M/S. ENSIGHT PHARMACEUTICALS INC in the Philippines may import Gatifloxacin as an active pharmaceutical ingredient (API) for local formulation and packaging. Their procurement is typically in bulk quantities, aligned with production schedules and market demand forecasts.

Understanding these segments is crucial for tailoring marketing strategies, forecasting demand, and ensuring efficient supply chain management.

The importation of Gatifloxacin into the top five importing countries involves specific regulatory processes:

• Iraq:
• Regulatory Authority: Iraqi Ministry of Health.
• Import Registration Process: Importers must obtain approval from the Iraqi Ministry of Health, which includes submitting product dossiers, certificates of analysis, and compliance with local pharmaceutical standards.
• Estimated Timeline for Registration: Approximately 6-12 months, depending on the completeness of documentation and regulatory reviews.
• Import Tariff/Duty for HS 30049099: Typically ranges from 5% to 10%, subject to changes based on government policies.

• Uganda:
• Regulatory Authority: National Drug Authority (NDA).
• Import Registration Process: Requires submission of a product dossier, including manufacturing licenses, GMP certificates, and product samples.
• Estimated Timeline for Registration: Approximately 6-9 months.
• Import Tariff/Duty for HS 30049099: Generally around 0% to 5%, with potential exemptions for essential medicines.

• Ukraine:
• Regulatory Authority: State Service of Ukraine on Medicines and Drugs Control.
• Import Registration Process: Involves submission of a comprehensive dossier, including clinical trial data, GMP compliance, and product labeling in Ukrainian.
• Estimated Timeline for Registration: Approximately 12-18 months.
• Import Tariff/Duty for HS 30049099: Typically around 5%, with possible reductions for essential medicines.

• Saudi Arabia:
• Regulatory Authority: Saudi Food and Drug Authority (SFDA).
• Import Registration Process: Requires submission of product dossiers, GMP certificates, and compliance with SFDA guidelines.
• Estimated Timeline for Registration: Approximately 6-12 months.
• Import Tariff/Duty for HS 30049099: Generally 5%, with potential exemptions for certain pharmaceuticals.

• Eswatini:
• Regulatory Authority: Eswatini Medicines Regulatory Authority (EMRA).
• Import Registration Process: Involves submission of product information, GMP certificates, and adherence to EMRA guidelines.
• Estimated Timeline for Registration: Approximately 6-9 months.
• Import Tariff/Duty for HS 30049099: Typically around 0% to 5%, with possible exemptions for essential medicines.

Importers should consult the respective regulatory authorities for the most current information, as regulations and tariffs are subject to change.

The demand for Gatifloxacin in importing countries is influenced by several factors:

• Disease Prevalence: Gatifloxacin is used to treat various bacterial infections, including respiratory tract infections and certain types of tuberculosis. High prevalence rates of these conditions in countries like Iraq and Uganda drive the need for effective antibiotics.

• Government Healthcare Programs: National health initiatives aimed at combating infectious diseases often include antibiotics like Gatifloxacin in their treatment protocols. For instance, Uganda's Ministry of Health has programs targeting respiratory infections, necessitating a steady supply of appropriate medications.

• Universal Health Coverage Expansion: Efforts to expand healthcare access, particularly in developing nations, increase the demand for essential medicines. As more individuals gain access to healthcare services, the need for antibiotics like Gatifloxacin rises correspondingly.

• WHO Essential Medicines List Procurement: While Gatifloxacin is not currently listed on the WHO Model List of Essential Medicines, its inclusion in national essential medicines lists can influence procurement decisions. Countries often align their procurement with WHO recommendations to ensure the availability of critical medications.

• Tender-Based Purchasing: Many governments and large healthcare organizations procure medicines through tender systems, which can lead to bulk purchasing of antibiotics like Gatifloxacin. This approach ensures cost-effectiveness and consistent supply for public health facilities.

With 93 buyers across 46 countries, the market for Gatifloxacin demonstrates a broad and diverse demand base, presenting opportunities for suppliers to cater to varying healthcare needs globally.